SCARLETRED is proud to announce the publication of a new peer-reviewed study in the Journal of the American Academy of Dermatology (JAAD) - one of the most prestigious scientific journals in dermatology worldwide.  

The study “AI-Powered Imaging for Objective Psoriasis Severity Assessment at Home: Feasibility and Reliability in a Randomized Clinical Trial” demonstrates that AI-powered smartphone imaging can reliably and objectively assess psoriasis severity in the home setting – reducing the need for frequent clinic visits while enabling consistent, scalable disease monitoring.

Bridging the gap between clinic and home

Psoriasis is a chronic inflammatory skin condition affecting 125 million people globally. Reliable disease monitoring has traditionally required regular in-person visits. This study provides clinical evidence that this gap can be closed with the right technology.  

Using Scarletred®Vision, powered by the agentic ARORA®AI, the certified Software as a Medical Device (SaMD) enables patients to capture standardized skin images from their homes. The collected skin data is then assessed with clinical-grade accuracy. The results of the randomized clinical trial confirm both feasibility and reliability of this approach.

A milestone for AI-driven digital dermatology

The publication in JAAD represents peer-reviewed validation at the highest level – a critical incentive for adoption in clinical practice and regulatory frameworks. The study is proof that AI-powered remote skin assessment is no longer a concept, but a clinically proven, feasible reality.

“This peer-reviewed publication in JAAD marks a major milestone for our team and validates the rigorous clinical science behind our technology. The study confirms that standardized mobile imaging, together with SCARLETRED’s ARORA®AI, can generate reliable primary clinical endpoint data in psoriasis, both in the clinic and in a decentralized home setting”, says Dr. Harald Schnidar, CEO and Founder of SCARLETRED.

"This study shows that high-quality, objective skin assessment no longer has to happen inside a clinic. This proof has real implications for how we design care for patients with chronic skin conditions”, adds Monika Molnarova, Biomedical Engineer and Senior Data Scientist at SCARLETRED.

Dr. Harald Schnidar and Monika Molnarova co-authored the recent study published in JAAD.

About the study

The research was conducted in close collaboration with CHDR (Centre for Human Drug Research), combining expertise in AI, digital health, and clinical research. Contributing authors include Dr. Harald Schnidar and Monika Molnarova from SCARLETRED, alongside Mariona Oliver, Menthe Bergmans, Rahul Ranjan, Vasileios Exadaktylos, Tessa Niemeyer van der Kolk, Marieke M.B. Seyger, Leonard Wee, Deepak M.W. Balak, Martijn B.A. van Doorn, Robert Rissmann, Jannik Rousel, The Next Generation ImmunoDermatology Consortium (NGID).

Find the publication here.

‍

‍